Mechanical Device Malfunction of the HeartMate II Versus the HeartMate 3 Left Ventricular Assist Device: The Rotterdam Experience

被引:1
|
作者
van der Heiden, Cornelis W. [1 ]
Zijderhand, Casper F. [1 ,2 ]
Veen, Kevin M. [2 ]
Constantinescu, Alina A. [1 ]
Manintveld, Olivier C. [1 ]
Brugts, Jasper J. [1 ]
Bekkers, Jos A. [2 ]
Birim, Ozcan [2 ]
Bogers, Ad J. J. C. [2 ]
Caliskan, Kadir [1 ]
机构
[1] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiol, Thoraxctr, Room RG 431,Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiothorac Surg, Thoraxctr, Rotterdam, Netherlands
关键词
left ventricular assist device; HeartMate II; HeartMate; 3; mechanical device malfunction; CIRCULATORY SUPPORT;
D O I
10.1097/MAT.0000000000001877
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Mechanical device malfunction remains a known issue in left ventricular assist devices (LVADs). We investigated the incidence of mechanical device malfunction in the HeartMate II and HeartMate 3 LVADs. We conducted a retrospective study of all HeartMate II and HeartMate 3 LVADs implanted in our center. We evaluated major malfunction, potential major malfunction, minor malfunction, and need of device exchange. In total, 163 patients received an LVAD; in 63 (39%) a HeartMate II, and in 100 (61%) a HeartMate 3, median support time of respectively 24.6 months (interquartile range [IQR]: 32.4) and 21.1 months [IQR: 27.2]. Mechanical device malfunction, consisting of both major and potential major malfunction, occurred significantly less in the HeartMate 3 patients with a hazard ratio (HR) of 0.37 (95% confidence interval [CI]: 0.15-0.87, p = 0.022). Major malfunction alone occurred significantly less in HeartMate 3 patients with a HR of 0.18 (95% CI: 0.05-0.66, p = 0.009). HeartMate 3 patients had a significantly decreased hazard of a pump or outflow graft exchange (HR 0.13, 95% CI: 0.08-0.81, p = 0.008). System controller defects occurred significantly less in HM 3 patients (p = 0.007), but battery-clips defects occurred significantly more in HM 3 patients (p = 0.039). Major device malfunction including pump or outflow graft exchange occurred significantly less in HeartMate 3 compared to HeartMate II, while minor malfunctions were similar. Periodical assessment of the technical integrity of the device remains necessary during long-term LVAD support.
引用
收藏
页码:E80 / E85
页数:6
相关论文
共 50 条
  • [31] Laparoscopic Splenectomy in a Patient with a Heartmate® II Left Ventricular Assist Device
    Samoukovic, Gordan
    Vassiliou, Melina
    Giannetti, Nadia
    Al-Sabah, Salman
    Lash, Vynka
    Cecere, Renzo
    JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES, 2011, 21 (06): : 535 - 538
  • [32] Clinical Courses of HeartMate II Left Ventricular Assist Device Thrombosis
    Kittipibul, Veraprapas
    Xanthopoulos, Andrew
    Hurst, Thomas E.
    Fukamachi, Kiyotaka
    Blackstone, Eugene H.
    Soltesz, Edward
    Starling, Randall C.
    ASAIO JOURNAL, 2020, 66 (02) : 153 - 159
  • [33] Eptifibatide for the Treatment of HeartMate II Left Ventricular Assist Device Thrombosis
    Al-Quthami, Adeeb H.
    Jumean, Marwan
    Kociol, Robb
    Duc Thinh Pham
    Kiernan, Michael
    DeNofrio, David
    Kapur, Navin K.
    CIRCULATION-HEART FAILURE, 2012, 5 (04) : E68 - E70
  • [34] Percutaneous Lead Dysfunction in the HeartMate II Left Ventricular Assist Device
    Kalavrouziotis, Dimitri
    Tong, Michael Z.
    Starling, Randall C.
    Massiello, Alex
    Soltesz, Edward
    Smedira, Nicholas G.
    Fryc, Robert
    Heatley, Gerald
    Farrar, David J.
    Moazami, Nader
    ANNALS OF THORACIC SURGERY, 2014, 97 (04): : 1373 - 1378
  • [35] Endoscopic tunneling of HeartMate II left ventricular assist device driveline
    Nagpal, A. Dave
    Larsen, Brianne K.
    Smedira, Nicholas G.
    Soltesz, Edward G.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 145 (01): : 297 - 298
  • [36] Successful Weaning and Explantation of the Heartmate II Left Ventricular Assist Device
    Lamarche, Yoan
    Kearns, Mark
    Josan, Kiranbir
    Bashir, Jamil
    Ignaszewski, Andrew
    Kaan, Annemarie
    Kealy, Jennifer
    Moss, Robert
    Cheung, Anson
    CANADIAN JOURNAL OF CARDIOLOGY, 2011, 27 (03) : 358 - 362
  • [37] Lidocaine toxicity in the setting of HeartMate II left ventricular assist device
    Tunney, R. K., Jr.
    Whyte, K.
    DeAntonio, H. J.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2018, 43 (05) : 733 - 736
  • [38] Low thromboembolic risk with the heartmate II left ventricular assist device
    John, R.
    Kamdar, F.
    Toninato, C.
    Boyle, A.
    Colvin-Adams, M.
    Liao, K.
    Miller, L.
    Joyce, L.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (02): : S253 - S253
  • [39] Hybrid approach to HeartMate II left ventricular assist device exchange
    Timek, Tomasz A.
    Hooker, Robert L.
    Khaghani, Asghar
    Merhi, William
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2013, 145 (03): : 878 - 880
  • [40] De-Novo Human Leukocyte Antigen Allosensitization on HeartMate 3 versus HeartMate II Left Ventricular Assist Device Recipients
    Jain, R.
    Habal, M.
    Restaino, S.
    Latif, F.
    Truby, L.
    Clerkin, K.
    Raikhelkar, J.
    Fried, J.
    Masoumi, A.
    Yuzefpolskaya, M.
    Colombo, P.
    Sayer, G.
    Takayama, H.
    Takeda, K.
    Naka, Y.
    Farr, M.
    Uriel, N.
    Topkara, V. K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S16 - S16